Caris Life Sciences (NASDAQ:CAI) Sets New 1-Year Low – Time to Sell?

Caris Life Sciences, Inc. (NASDAQ:CAI) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $21.09 and last traded at $21.13, with a volume of 404299 shares traded. The stock had previously closed at $22.17.

Wall Street Analyst Weigh In

CAI has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. Canaccord Genuity Group upped their price target on shares of Caris Life Sciences from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Monday, December 22nd. Evercore set a $38.00 price target on shares of Caris Life Sciences in a research note on Monday, January 5th. Finally, Wall Street Zen raised shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $34.00.

Caris Life Sciences Price Performance

The firm has a 50-day moving average of $25.96. The company has a current ratio of 9.93, a quick ratio of 9.36 and a debt-to-equity ratio of 0.79.

Insider Transactions at Caris Life Sciences

In other Caris Life Sciences news, insider Luke Thomas Power sold 62,250 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the sale, the insider owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. This represents a 38.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 7.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Caris Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in CAI. MetLife Investment Management LLC grew its stake in Caris Life Sciences by 84.0% during the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after purchasing an additional 755 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Caris Life Sciences by 99,900.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after buying an additional 999 shares in the last quarter. Olistico Wealth LLC acquired a new stake in shares of Caris Life Sciences during the 4th quarter worth approximately $31,000. Police & Firemen s Retirement System of New Jersey increased its stake in shares of Caris Life Sciences by 15.0% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 11,932 shares of the company’s stock valued at $322,000 after acquiring an additional 1,560 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of Caris Life Sciences during the 4th quarter valued at $81,000.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.